# US 2021/0341480 A1 · Viral testing in saliva

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341480 A1
- Document ID: US20210341480A1
- Status: Published application
- Kind: A1
- Application number: 17/244,333
- Filed: 2021-04-29
- Published: 2021-11-04
- Earliest claimed: 2020-04-29
- Inventors: Shi-Long Lu; Brian L. Harry; Jose P. Zevallos; Robert E. Blomquist; Xin Yao; Yue Qiu; Marsha T. Tharakan
- Web page: https://patentgrep.com/patent/US20210341480A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- G01N 33/56983: {Viruses}
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- G01N 33/6854: {Immunoglobulins}
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Saliva-based testing for viruses including SARS-CoV-2 are provided. Simple collection methods allow for at-home collection, reducing the risk and burden on healthcare workers using conventional testing methods. Tests can quantitatively analyze both viral nucleic acids to assess viral load as well as virus-specific antibodies to track disease progression and potential immunity.

## Claims

### Claim 1

A method of detecting a viral infection, the method comprising:
providing a saliva sample from a patient;
performing one or more assay(s) to detect viral nucleic acid and/or virus-specific antibodies or antigens in the saliva sample; and
diagnosing the patient as having been infected with the virus upon detection of the viral nucleic acid, or the virus-specific antibodies or antigens in the saliva sample.

### Claim 2 (depends on 1)

The method of claim 1 wherein the virus is a respiratory virus.

### Claim 3 (depends on 2)

The method of claim 2, wherein the virus is a member selected from the group consisting of paramyxoviridae, picornaviradae, coronaviridae, parvoviridae, and enteroviridae.

### Claim 4 (depends on 2)

The method of claim 2, wherein the virus is a virus causative of severe acute respiratory syndrome.

### Claim 5 (depends on 4)

The method of claim 4, wherein the virus is a SARS-CoV-2 virus.

### Claim 6 (depends on 1)

The method of claim 1, wherein the performing step comprises performing assays to detect viral nucleic acid and virus-specific antibodies in the saliva sample.

### Claim 7 (depends on 1)

The method of claim 1, wherein the performing step comprises performing PCR on nucleic acids from the saliva sample using primers specific for viral nucleic acid.

### Claim 8 (depends on 7)

The method of claim 7, wherein the viral-nucleic acid-specific primers target one or more of the N, ORF1ab, and E genes.

### Claim 9 (depends on 7)

The method of claim 7, further comprising quantifying the viral nucleic acid.

### Claim 10 (depends on 9)

The method of claim 9, wherein the quantifying step comprises performing Q-PCR.

### Claim 11 (depends on 7)

The method of claim 7, wherein the PCR is digital PCR (dPCR).

### Claim 12 (depends on 11)

The method of claim 11, wherein the dPCR is droplet digital PCR (ddPCR).

### Claim 13 (depends on 10)

The method of claim 10, further comprising determining severity of the infection based on quantification of viral nucleic acid.

### Claim 14 (depends on 7)

The method of claim 7, further comprising comparing viral nucleic acid quantities in a plurality of saliva samples obtained from the patient at successive time points and determining disease progression based on increases or decreases in the viral nucleic quantities over time.

### Claim 15 (depends on 7)

The method of claim 7, further comprising assessing a clinical course of treatment based on the viral nucleic acid quantity.

### Claim 16 (depends on 15)

The method of claim 15, wherein the clinical course of treatment is selected from the group consisting of intubation, ICU admission, discharge, time until intubation, time until discharge, and death.

### Claim 17 (depends on 1)

The method of claim 1, wherein the virus-specific antibodies comprise immunoglobulin A (IgA) or immunoglobulin G (IgG) antibodies.

### Claim 18 (depends on 17)

The method of claim 17, wherein the virus-specific antibodies comprise IgA and IgG antibodies.

### Claim 19 (depends on 15)

The method of claim 15, further comprising quantifying virus-specific antibodies.

### Claim 20 (depends on 19)

The method of claim 19, further comprising assessing a clinical course of treatment based on the quantity of the virus-specific IgA and IgG antibodies.

### Claim 21 (depends on 20)

The method of claim 20, wherein the clinical course of treatment is selected from one or more of intubation, ICU admission, discharge, time until intubation, time until discharge, and death.

### Claim 22 (depends on 17)

The method of claim 17, further comprising normalizing the quantities of virus-specific IgA and IgG antibodies against total IgA and IgG antibodies in the saliva sample.

### Claim 23 (depends on 1)

The method of claim 1, wherein the assay comprises an immunoassay.

### Claim 24 (depends on 23)

The method of claim 23, wherein the immunoassay is a biomarker-based assay.

### Claim 25 (depends on 24)

The method of claim 24, wherein the biomarker-based immunoassay is an enzyme-linked immunosorbent assay (ELISA), bead-based assay, a luminescent assay, a metal-linked immunosorbent assay, or a point-of-care immunochromatographic assay.
